公开(公告)号：WO2022159700A1

公开(公告)日：2022-07-28

申请号：PCT/US2022/013307

申请日：2022-01-21

Applicant: EMORY UNIVERSITY ,  CHILDREN'S HEALTHCARE OF ATLANTA, INC.

Inventor： MACDONALD, Tobey John ,  KENNEY, Anna, Marie ,  DEY, Abhinav ,  KIM, YongTae

IPC: B01L3/00 ,  C12N5/074 ,  G01N33/483

Abstract: The systems, devices, and methods utilize devices configured to generate multiple gradients of a plurality of different drugs in x and y coordinates at the same time so as to provide multiple drug concentrations and/or combinations. A device may include a first layer having a first set of one or more inlets in fluid communication with stem channels and a plurality of chambers, and a second layer having a second set of one or more inlets in fluid communication with stem channels and a plurality of chambers. The second layer may be disposed above the first layer so that the first set and the second set of inlets are offset and the plurality of chambers of the first and second layers align and overlap. The device may include a plurality of wells defined by the aligned the plurality of chambers of the first layer and the second layer.

公开(公告)号：WO2022150589A1

公开(公告)日：2022-07-14

申请号：PCT/US2022/011618

申请日：2022-01-07

Applicant: EMORY UNIVERSITY ,  CHILDREN'S HEALTHCARE OF ATLANTA, INC.

Inventor： HENRY, Curtis J. ,  RAIKAR, Sunil S. ,  RAFIQ, Sarwish

IPC: C12N5/078 ,  C07K14/52

Abstract: This disclosure relates to therapeutics containing IL-37, chimeric antigen receptors, nucleic acids, or vectors encoding the same. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering a nucleic acid or vector encoding interleukin-37 to a subject diagnosed with cancer and administering T cells expressing a chimeric antigen receptor to the subject. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering a nucleic acid or vector encoding interleukin-37 and a chimeric antigen receptor to a subject diagnosed with cancer.

公开(公告)号：WO2022020745A1

公开(公告)日：2022-01-27

申请号：PCT/US2021/043017

申请日：2021-07-23

Applicant: EMORY UNIVERSITY ,  CHILDREN'S HEALTHCARE OF ATLANTA, INC.

Inventor： HENRY, Curtis J. ,  HAMILTON, Jamie A. G. ,  RAIKAR, Sunil S. ,  ROSS, Anthony ,  LEE, Miyoung

IPC: A61P35/00 ,  A61K35/17 ,  A61K48/00 ,  C07K14/705

Abstract: This disclosure relates to uses of galectin-9 specific binding agents and chimeric antigen receptors in methods of treating cancer such as hematological cancers or solid tumors. In certain embodiments, the galectin-9 specific binding agent is a TIM3, CD44, CD40, CLEC7a (Dectin-1), or CD137 (4- IBB) extracellular domain, an anti-galectin-9 antibody, specific binding single chain antibody, fragment, or variant thereof. In certain embodiments, cancer treatment is a cell-based therapy using chimeric antigen receptors having a galectin-9 targeting sequence.

公开(公告)号：WO2021183640A1

公开(公告)日：2021-09-16

申请号：PCT/US2021/021698

申请日：2021-03-10

Applicant: EMORY UNIVERSITY ,  CHILDREN'S HEALTHCARE OF ATLANTA, INC.

Inventor： SORSCHER, Eric ,  HONG, Jeong ,  BEHBAHANI, Turang ,  RAB, Regina ,  EHRHARDT, Annette ,  JOSHI, Disha

IPC: A61K31/517 ,  A61K31/675 ,  A61K31/7056

Abstract: This disclosure relates to methods of treating cancer or initiating, enhancing, or prolonging an anti-tumor response in a subject in need thereof comprising administering to the subject an effective amount of a checkpoint inhibitor in combination with a purine cleaving enzyme or a vector encoding expression thereof, and a prodrug cleaved by said purine cleaving enzyme. In certain embodiments, this disclosure relates to methods of treating cancer or initiating, enhancing, or prolonging an anti-tumor response in a subject in need thereof comprising administering to the subject an effective amount of a checkpoint inhibitor in combination with a purine cleaving enzyme, or a vector encoding expression thereof, in the absence of a prodrug cleaved by said purine cleaving enzyme.

公开(公告)号：WO2020167813A1

公开(公告)日：2020-08-20

申请号：PCT/US2020/017727

申请日：2020-02-11

Applicant: EMORY UNIVERSITY ,  CHILDREN'S HEALTHCARE OF ATLANTA, INC.

Inventor： MOORE, Martin L. ,  TODD, Sean ,  STOBART, Christopher C.

IPC: A61K39/12 ,  C12N15/86 ,  C12N15/79

Abstract: This disclosure relates to a chimeric respiratory syncytial virus encoding a chimeric RSV and hMPV F protein and uses of the chimeric virus or components therein in a vaccine. In certain embodiments, this disclosure relates to a live attenuated vaccine comprising an RSV backbone substituting the F proteins of RSV, for a chimeric RSV and hMPV F protein.

公开(公告)号：WO2020072919A1

公开(公告)日：2020-04-09

申请号：PCT/US2019/054724

申请日：2019-10-04

Applicant: CHILDREN'S HEALTHCARE OF ATLANTA, INC.

Inventor： REISNER, Andrew ,  BLACKWELL, Laura ,  SAYEED, Iqbal

IPC: G01N33/53 ,  G01N33/68 ,  G01N33/48

Abstract: Disclosed herein is the use of plasma osteopontin (OPN) levels for diagnosing and predicting the severity and outcomes in traumatic brain injury (TBI), such as adult and pediatric TBI. The disclosed method can be used to diagnose TBI in any subject, such as pediatric, adult, and geriatric subjects. However, the method is particularly useful in pediatric subjects where current methods are insufficient. A particularly useful advantage of the disclosed methods is the ability to diagnose Abusive Head Trauma (AHT) in a pediatric subject.

公开(公告)号：WO2017136356A2

公开(公告)日：2017-08-10

申请号：PCT/US2017/015872

申请日：2017-01-31

Applicant: EMORY UNIVERSITY ,  GEORGIA TECH RESEARCH CORPORATION ,  CHAPMAN UNIVERSITY ,  CHILDREN'S HEALTHCARE OF ATLANTA, INC.

Inventor： LAM, Wilbur A. ,  HANSEN, Caroline ,  SAKURAI, Yumiko ,  LYON, Andrew

IPC: A61K9/14 ,  A61K38/37

CPC classification number: A61K9/5073 ,  A61K9/0019 ,  A61K9/5052 ,  A61K9/5089 ,  A61K38/37

Abstract: This disclosure relates to microcapsule particles for targeted delivery of drugs. In certain embodiments, the particles comprise polyelectrolyte polymers, e.g., layers of anionic polymers and cationic polymers. In certain embodiments, the particles have a fibrinogen coating. In certain embodiments, the particles contain a polysaccharide core and/or a polysaccharide coating encapsulating drugs, proteins, clotting agents, coagulation factors, or anticoagulants. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of or duration of bleeding. In certain embodiments, this disclosure contemplates methods of using particles disclosed herein to prevent or reduce onset of blood clotting.

公开(公告)号：WO2016205389A1

公开(公告)日：2016-12-22

申请号：PCT/US2016/037658

申请日：2016-06-15

Applicant: EMORY UNIVERSITY ,  CHILDREN'S HEALTHCARE OF ATLANTA, INC.

Inventor： MOORE, Martin L. ,  LEE, Sujin ,  NGUYEN, Minh Trang

IPC: A61K39/12 ,  A61K39/13 ,  A61K39/145

CPC classification number: A61K39/125 ,  A61K39/12 ,  A61K2039/5252 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/70 ,  A61P31/16 ,  C12N2770/32334

Abstract: This disclosure relates to multivalent enterovirus vaccine compositions and uses related thereto. In certain embodiments, the disclosure relates to vaccine compositions comprising multivalent, mixtures of enterovirus (for example HRV) serotypes or recombinantly produced variants or recombinantly produced viral capsid proteins. In certain embodiments, the disclosure relates to methods of immunization comprising administering an effective amount of compositions disclosed herein to a subject diagnosed with, exhibiting symptoms of, or at risk of an enterovirus infection.

Abstract translation: 本公开涉及多价肠病毒疫苗组合物及其相关用途。 在某些实施方案中，本公开涉及包含多价，肠道病毒（例如HRV）血清型或重组产生的变体或重组产生的病毒衣壳蛋白的混合物的疫苗组合物。 在某些实施方案中，本公开涉及免疫方法，其包括将有效量的本文公开的组合物施用于被诊断患有肠道病毒感染的症状或具有肠病毒感染风险的受试者。

公开(公告)号：WO2015034984A1

公开(公告)日：2015-03-12

申请号：PCT/US2014/053990

申请日：2014-09-04

Applicant: EMORY UNIVERSITY ,  CHILDREN'S HEALTHCARE OF ATLANTA, INC.

Inventor： MORRIS, Claudia R.

IPC: A23L1/29 ,  A23L1/302 ,  C12P7/64

CPC classification number: A61K31/23 ,  A23L33/12 ,  A23L33/135 ,  A23L33/15 ,  A23L33/155 ,  A23L33/16 ,  A23L33/175 ,  A23L33/40 ,  A23V2002/00 ,  A61K9/0056 ,  A61K9/145 ,  A61K9/2013 ,  A61K9/4858 ,  A61K31/047 ,  A61K31/07 ,  A61K31/122 ,  A61K31/19 ,  A61K31/20 ,  A61K31/202 ,  A61K31/205 ,  A61K31/22 ,  A61K31/231 ,  A61K31/232 ,  A61K31/355 ,  A61K31/375 ,  A61K31/385 ,  A61K31/4375 ,  A61K31/473 ,  A61K31/59 ,  A61K31/661 ,  A61K31/7004 ,  A61K33/18 ,  A61K33/24 ,  A61K33/26 ,  A61K33/30 ,  A61K33/32 ,  A61K33/34 ,  A61K33/42 ,  A61K35/741 ,  A61K38/46 ,  A61K45/06 ,  A61K2035/115 ,  A61K2300/00

Abstract: This disclosure relates to nutritional formulas and uses for treating or preventing a gastrointestinal condition and/or motor-planning speech and/or coordinator difficulties. In certain embodiments, this disclosure relates to a nutritional formula comprising medium 5 chain fatty acids, or esters thereof (such as and tri-, di-, mono-glycerides, or alkyl esters), unsaturated fatty acids, and a vitamin E and optionally other nutrients. In certain embodiments, any of the compounds or nutrients may be in alternative salt forms.

Abstract translation: 本公开涉及用于治疗或预防胃肠道疾病和/或运动规划语音和/或协调者困难的营养配方和用途。 在某些实施方案中，本公开涉及包含培养基5链脂肪酸或其酯（例如和三 - ，二 - ，单 - 甘油酯或烷基酯），不饱和脂肪酸和维生素E的营养配方， 其他营养。 在某些实施方案中，任何化合物或营养物可以是替代盐形式。

公开(公告)号：WO2014121176A2

公开(公告)日：2014-08-07

申请号：PCT/US2014/014377

申请日：2014-02-03

Applicant: EMORY UNIVERSITY ,  CHILDREN'S HEALTHCARE OF ATLANTA, INC.

Inventor： LI, Renhao

CPC classification number: C07K16/28 ,  C07K16/2896 ,  C07K16/40 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/35 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/70 ,  C07K2317/92

Abstract: This disclosure relates to specific binding agents, such as isolated recombinant monoclonal antibodies, that bind Glycoprotein Ib alpha (GPIba). More specifically, the disclosure relates to methods of preventing platelet ectodomain shedding, preventing platelet clearance and degradation, maintaining and increasing platelet blood serum levels for in vitro or in vivo applications. In some embodiments, the disclosure relates to the production, diagnostic use, and therapeutic use of monoclonal and polyclonal antibodies, and the antigen-binding fragments thereof, which specifically bind GPIba. Aspects of the disclosure also relate to hybridomas or other cell lines expressing such antibodies for specific binding agent. Compositions and methods for inhibiting shedding, clearance, or degradation, or treating diseases associated with GPIba ectodomain shedding are also described.

Abstract translation: 本公开涉及结合糖蛋白Ibα（GPIba）的特异性结合剂，例如分离的重组单克隆抗体。 更具体而言，本公开涉及预防血小板胞外域脱落，预防血小板清除和降解，维持和增加血小板血清水平以用于体外或体内应用的方法。 在一些实施方案中，本公开涉及特异性结合GPIba的单克隆和多克隆抗体及其抗原结合片段的生产，诊断用途和治疗用途。 本公开的方面还涉及表达用于特异性结合剂的这种抗体的杂交瘤或其他细胞系。 还描述了用于抑制脱落，清除或降解或治疗与GPIba胞外域脱落有关的疾病的组合物和方法。